title: A 9-year experience with 126 pancreas transplants with portal enteric drainage.
abstract: OBJECTIVE
  A novel technique of pancreas transplantation (PTX) with portal venous delivery of insulin and enteric exocrine drainage (portal enteric) was developed at our center to improve the PTX procedure.
  
  
  METHODS
  Case series.
  
  
  METHODS
  Single-center experience at a university hospital.
  
  
  METHODS
  From October 1990 through December 1999, we performed 126 PTXs with portal enteric drainage, including 90 simultaneous kidney PTXs (SKPT) and 36 solitary PTXs (18 sequential PTXs after kidney transplantation and 18 PTXs alone).
  
  
  METHODS
  Patient and graft survival rates; medical and surgical morbidity. Three groups, representing 3 eras of immunosuppression, were compared. Thirty patients underwent SKPT with muromonab-CD3 induction and cyclosporine-based therapy in era 1 (October 1990 through June 1995); 42 SKPTs received tacrolimus and mycophenolate mofetil-based immunosuppression without antibody induction in era 2 (July 1995 through May 1998); and 18 SKPTs were performed in era 3 (June 1998 through December 1999) with either basiliximab or daclizumab induction.
  
  
  RESULTS
  One-year patient survival rates after SKPT were 77% in era 1, 93% in era 2, and 100% in era 3 (P =.03). The 1-year kidney graft survival rates were 77% in era 1, 93% in era 2, and 94% in era 3 (P =.08). The 1-year pancreas graft survival rates after SKPT were 60% in era 1, 83% in era 2, and 83% in era 3 (P =.06). The incidences of rejection (63% vs. 33% vs. 39%; P<.001) and thrombosis (20% vs. 7% vs. 6%; P<.001) were decreased in eras 2 and 3.
  
  
  CONCLUSIONS
  Simultaneous kidney PTXs with portal enteric drainage can be performed with improved outcomes.
authors.affiliation: Department of Surgery, University of Tennessee, 956 Court Ave, Suite A202, Memphis, TN 38163-2116, USA. rstratta@utmem.edu
authors.forename: R J
authors.initials: RJ
authors.lastname: Stratta
authors.forename: A O
authors.initials: AO
authors.lastname: Gaber
authors.forename: M H
authors.initials: MH
authors.lastname: Shokouh-Amiri
authors.forename: H P
authors.initials: HP
authors.lastname: Grewal
authors.forename: M F
authors.initials: MF
authors.lastname: Egidi
authors.forename: A T
authors.initials: AT
authors.lastname: Kizilisik
authors.forename: D K
authors.initials: DK
authors.lastname: Hathaway
authors.forename: L W
authors.initials: LW
authors.lastname: Gaber
mesh_terms: D000293:Adolescent; D000328:Adult; D000714:Anastomosis, Surgical; D002648:Child; D004386:Duodenum / Q000601:surgery; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000379:methods / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000379:methods* / Q000401:mortality; D011169:Portal Vein / Q000601:surgery*; D015996:Survival Rate
chemical_list: D007166:Immunosuppressive Agents